Drug Profile
AZD 4750
Alternative Names: AZD4750Latest Information Update: 06 May 2005
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 21 Mar 2005 Discontinued - Phase-I for Multiple sclerosis in Sweden (unspecified route)
- 29 Jan 2004 Phase-I clinical trials in Multiple sclerosis in Sweden (unspecified route)
- 06 May 2003 Preclinical trials in Multiple sclerosis in Sweden (unspecified route)